Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 10,939 | 7,492 | 20,723 | 16,322 |
| Research and development | 20,355 | 19,453 | 50,982 | 36,996 |
| Selling, general and administrative | 82,138 | 69,170 | 156,214 | 133,172 |
| Total operating expenses | 113,432 | 96,115 | 227,919 | 186,490 |
| Income (loss) from operations | 16,429 | (14,611) | 7,340 | (39,140) |
| Other income (expense): | ||||
| Interest income | 2,279 | 2,076 | 4,554 | 4,613 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s SG&A?
- Arcutis Biotherapeutics, Inc. (ARQT) reported SG&A of $82.14M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s SG&A changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s SG&A increased by 18.7% year-over-year, from $69.17M to $82.14M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s SG&A?
- Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s SG&A has grown at a 31.0% compound annual growth rate (CAGR), from $122.12M to $274.55M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Arcutis Biotherapeutics, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude